According to The Fly, in a new note to investors today, an analyst has provided a rating update for Valeant Pharm International (VRX). Ram Selvaraju, an analyst with H.C. Wainwright, has upgraded their rating on VRX to Buy.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -14.0% and a 19.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Read also: MYOS RENS Technology (MYOS) Stock Fires Up to the Roof; Here’s Why
The the analyst consensus on Valeant Pharm International is currently a Moderate Buy rating.
Valeant Pharm International’s market cap is currently C$11.05B and has a P/E ratio of –. The company has a Price to Book ratio of 2.71.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
